Sign in Subscribe
Antiparkinson agents

New Study Reveals Positive Effects of Levodopa-Entacapone-Carbidopa Infusion on Parkinson's Disease Symptoms

Strategic Insights

— 1 min read

A new study published in the Journal of Neural Transmission has found that the routine use of levodopa-entacapone-carbidopa intrajejunal infusion (LECIG) significantly reduces the burden of non-motor symptoms (NMS) in advanced Parkinson's disease patients. The study, known as the ELEGANCE study (NCT05043103), collected real-world data on long-term efficacy, safety, and patient-reported outcomes from 167 patients treated with LECIG.

Key Takeaways:

  • The ELEGANCE study enrolled patients prescribed LECIG as part of routine clinical care and evaluated them at three time points: before treatment, after 3-6 months, and after 6-12 months.
  • The study found that the mean Non-Motor Symptoms Scale (NMSS) total scores decreased significantly from baseline at both the 3-6 month and 6-12 month follow-ups, indicating an overall improvement in NMS burden.
  • The significant reductions in scores for the domains of 'sleep/fatigue' and 'gastrointestinal (GI) tract' were sustained at the 6-12 month follow-up.
  • The study concluded that routine use of LECIG for up to 12 months reduced the overall NMS burden, with particular impact on sleep- and GI-related symptoms.

Statistics:

  • The study included 167 LECIG-treated patients from 37 centers with at least one measure of effectiveness at the 3-6 month or 6-12 month follow-ups.
  • The mean NMSS total scores decreased by 15.2 points at the 3-6 month follow-up and by 21.4 points at the 6-12 month follow-up compared to baseline.
  • 7 out of 9 individual domains showed significant improvements in scores from baseline to the 3-6 month follow-up.

Sources:

  • NewsRx. New Data from Academic Teaching Hospital Illuminate Findings in Parkinson's Disease (Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson's disease-interim analysis of the ELEGANCE study). Health & Medicine Week. October 24, 2025; p 2445.
  • Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson's disease-interim analysis of the ELEGANCE study. Journal of Neural Transmission, 2025.

Read more